124 related articles for article (PubMed ID: 25058214)
1. Reconsideration of age as a contraindication for curative therapy of sickle cell disease.
King AA; DiPersio JF
JAMA; 2014 Jul; 312(1):33-4. PubMed ID: 25058214
[No Abstract] [Full Text] [Related]
2. Allogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia.
Bernaudin F; Pondarré C; Galambrun C; Thuret I
Adv Exp Med Biol; 2017; 1013():89-122. PubMed ID: 29127678
[TBL] [Abstract][Full Text] [Related]
3. Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease.
Saraf SL; Oh AL; Patel PR; Jalundhwala Y; Sweiss K; Koshy M; Campbell-Lee S; Gowhari M; Hassan J; Peace D; Quigley JG; Khan I; Molokie RE; Hsu LL; Mahmud N; Levinson DJ; Pickard AS; Garcia JG; Gordeuk VR; Rondelli D
Biol Blood Marrow Transplant; 2016 Mar; 22(3):441-8. PubMed ID: 26348889
[TBL] [Abstract][Full Text] [Related]
4. Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies.
Gaziev J; Marziali S; Paciaroni K; Isgrò A; Di Giuliano F; Rossi G; Marziali M; De Angelis G; Alfieri C; Ribersani M; Andreani M; Palmieri MG; Placidi F; Romigi A; Izzi F; Floris R; Mercuri NB
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1531-1540. PubMed ID: 28602890
[TBL] [Abstract][Full Text] [Related]
5. Cord blood transplantation (CBT) in hemoglobinopathies. Eurocord.
Miniero R; Rocha V; Saracco P; Locatelli F; Brichard B; Nagler A; Roberts I; Yaniv I; Beksac M; Bernaudin F; Gluckman E
Bone Marrow Transplant; 1998 Jul; 22 Suppl 1():S78-9. PubMed ID: 9715898
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease.
Williams KM; Dietzen D; Hassoun AA; Fennoy I; Bhatia M
Pediatr Blood Cancer; 2014 Dec; 61(12):2307-9. PubMed ID: 24938636
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic stem-cell transplantation for adults with sickle cell disease.
Abboud MR
N Engl J Med; 2009 Dec; 361(24):2380-1. PubMed ID: 20007564
[No Abstract] [Full Text] [Related]
8. Hematopoietic cell transplantation for hemoglobinopathies.
Krishnamurti L; Bunn HF; Williams AM; Tolar J
Curr Probl Pediatr Adolesc Health Care; 2008 Jan; 38(1):6-18. PubMed ID: 18068866
[No Abstract] [Full Text] [Related]
9. Indications and results of progenitor cell transplant in congenital haemopathies (except Fanconi anaemia).
Souillet G
Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S28-33. PubMed ID: 9630321
[No Abstract] [Full Text] [Related]
10. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel.
Angelucci E; Matthes-Martin S; Baronciani D; Bernaudin F; Bonanomi S; Cappellini MD; Dalle JH; Di Bartolomeo P; de Heredia CD; Dickerhoff R; Giardini C; Gluckman E; Hussein AA; Kamani N; Minkov M; Locatelli F; Rocha V; Sedlacek P; Smiers F; Thuret I; Yaniv I; Cavazzana M; Peters C;
Haematologica; 2014 May; 99(5):811-20. PubMed ID: 24790059
[TBL] [Abstract][Full Text] [Related]
11. Advances in allogeneic stem cell transplantation for hemoglobinopathies.
Al Jefri AH
Hemoglobin; 2011; 35(5-6):469-75. PubMed ID: 21967642
[TBL] [Abstract][Full Text] [Related]
12. Successful management of sirolimus toxicity in a hematopoietic stem cell transplant patient using automated red blood cell exchange.
Nizzi F; Rees M; Salzberg D; Ngwube A
Transfusion; 2020 Dec; 60(12):3060-3063. PubMed ID: 32888326
[TBL] [Abstract][Full Text] [Related]
13. Genome Editing for the β-Hemoglobinopathies.
Porteus MH
Adv Exp Med Biol; 2017; 1013():203-217. PubMed ID: 29127682
[TBL] [Abstract][Full Text] [Related]
14. [Results of hematopoietic stem cell transplantation in hemoglobinopathies: thalassemia major and sickle cell disease].
Hladun R; Elorza I; Olivé T; Dapena JL; Llort A; Sánchez de Toledo J; Díaz de Heredia C
An Pediatr (Barc); 2013 Aug; 79(2):75-82. PubMed ID: 23402775
[TBL] [Abstract][Full Text] [Related]
15. On the road to gene therapy for beta-thalassemia and sickle cell anemia.
Bank A
Pediatr Hematol Oncol; 2008; 25(1):1-4. PubMed ID: 18231949
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
[TBL] [Abstract][Full Text] [Related]
17. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
Dong AC; Rivella S
Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of steroid-refractory gastrointestinal acute graft-versus-host disease with adjuvant vedolizumab therapy in a pediatric allogeneic stem cell transplant recipient.
Pai V; Abu-Arja R; Auletta JJ; Rangarajan HG
Pediatr Blood Cancer; 2020 Aug; 67(8):e28298. PubMed ID: 32472970
[No Abstract] [Full Text] [Related]
19. Progress toward safe and effective gene therapy for beta-thalassemia and sickle cell disease.
Lebensburger J; Persons DA
Curr Opin Drug Discov Devel; 2008 Mar; 11(2):225-32. PubMed ID: 18283610
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia.
Sadelain M
Curr Opin Hematol; 2006 May; 13(3):142-8. PubMed ID: 16567956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
